Vai al contenuto principale della pagina
Titolo: | Resistance to Ibritumomab in Lymphoma / / edited by Makoto Hosono, Jean-François Chatal |
Pubblicazione: | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2018 |
Edizione: | 1st ed. 2018. |
Descrizione fisica: | 1 online resource (161 pages) : illustrations |
Disciplina: | 616.99446 |
Soggetto topico: | Cancer research |
Cancer Research | |
Persona (resp. second.): | HosonoMakoto |
ChatalJean-François | |
Nota di contenuto: | Clinical Use and Efficacy of Ibritumomab in B-cell Lymphoma -- Biology and Pathology of B-cell lymphoma -- Resistance to Y-90 Ibritumomab Tiuxetan Therapy -- Features of Ibritumomab as Radionuclide Therapy -- Radiological Evaluation of Response and Resistance of Ibritumomab -- Characteristics of Ibritumomab as Radionuclide Therapy Agent -- Resistance and Heterogeneity of Intratumoral Antibody Distribution -- Radiation Dosimetry in Ibritumomab Therapy -- Combining RAIT and immune-based therapies to overcome resistance in cancer? -- Prospects for enhancing efficacy of radioimmunotherapy -- Index. |
Sommario/riassunto: | This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab. |
Titolo autorizzato: | Resistance to Ibritumomab in Lymphoma |
ISBN: | 3-319-78238-X |
Formato: | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione: | Inglese |
Record Nr.: | 9910298421103321 |
Lo trovi qui: | Univ. Federico II |
Opac: | Controlla la disponibilità qui |